Bone marrow stromal cells are essential for the differentiation, survival and proliferation of normal and leukemic human Blineage cells. Leukemic cells require stromal cell support for optimal proliferation and apoptotic resistance. Stromal cell contact can promote resistance to chemotherapeutic agents. In this study, we have made use of small molecular weight inhibitors and an established stromal cell-dependent pre-B-ALL cell line, BLIN-2, to investigate the role of the MAP kinase, PI3K/Akt, JAK/STAT and mTOR pathways in the promotion of leukemic cell growth in the presence of stromal cell support. Treatment with PI3K þ JAK, PI3K þ MEK, or MEK þ JAK inhibitor combinations resulted in an inhibition of proliferation as measured by DNA synthesis. However, only inhibition of both PI3K and MEK or both mTOR and MEK resulted in a dramatic increase in the number of annexinV þ /PI þ apoptotic events within a 24 h period. Our data suggest that stromal cellmediated apoptotic protection in B-lineage ALL is mediated by PI3K/mTOR and MEK via a synergistic mechanism(s).
Introduction
Normal B-cell development depends upon interaction with the bone marrow microenvironment (reviewed in Bertrand et al).
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This complex mixture of growth factors, extracellular matrix and stromal cells provides extrinsic signals that regulate the growth, differentiation and survival of B-cell precursors. Acute lymphoblastic leukemia (ALL) is often characterized by the clonal expansion of CD19 þ B-cell precursors of any one of several developmental stages. However, the precise role of the bone marrow microenvironment in the promotion of leukemic cell proliferation and survival is not fully characterized. Successful culture of freshly isolated leukemic blasts nearly always requires the presence of stromal cell feeder layers, suggesting that stromal cells play a role in modulating proliferation and survival of acute leukemia. 2, 3 Subtypes of B-lineage leukemia have been shown to localize to distinct stromal cell/microenvironmental regions of the bone marrow. 4 A unique stromal cell population, nurse cells, confers apoptotic protection to CLL cells. 5 Stromal cells have been documented to upregulate the expression of prosurvival proteins such as Bcl-2, blocking apoptosis in AML. 6 Moreover, protection from apoptotosis and chemotherapeutic agents has also been attributed to the presence of stromal cells. 7 Activation of caspase-3 by Ara-C or VP-16 treatment is reduced upon co-culture of B-lymphoblasts with stromal cell layers. 8 One recent study demonstrated that stromal cells would protect B-lineage ALL cell lines from cytarabine-and etoposide-induced cell death via a VCAM-1-dependent mechanism. 9 Fibronectins and integrins have also been implicated in protecting leukemic cells from the effects of chemotherapeutic agents. 10, 11 Many leukemias have alterations in MAP kinase signaling, of which there are three main groups: p38 MAPK , JNK and Raf/MEK/ ERK (reviewed in Lee and McCubrey 12 and Steelman et al 13 ) . In normal hematopoiesis, these can be activated by a variety of cytokine stimuli and other microenvironmental cues. These kinase pathways function to regulate cell cycle progression and apoptosis. In addition, the PI3K/Akt and JAK/STAT pathways can be activated by interaction with stromal cells and stromal cellderived growth factors. 13 These also play a role in regulating cell cycle progression and apoptosis either alone or in concert with MAP kinases. Furthermore, synergy between MAP kinase, PI3K/ Akt and JAK/STAT signaling has been suggested to contribute to cytokine-independent growth in hematopoietic cell lines. [12] [13] [14] [15] The mammalian target of rapamycin (mTOR) functions as a bridge between pathways regulating nutrient responses and those governing growth factor-derived proliferative and/or survival signals (reviewed in Gingras et al 16 ). Downstream targets of mTOR signaling include p70S6K and 4E-BP, which are key regulators of ribosomal synthesis and translational initiation.
In this study, we have made use of a stromal cell-dependent B-lineage ALL cell line model, BLIN-2, to investigate the role of MAP kinase, PI3K/Akt, JAK/STAT and mTOR pathways in the promotion of leukemic cell growth and survival in the context of stromal cell support. BLIN-2 is a pre-B-ALL cell line that requires viable bone marrow stromal cell or skin fibroblast cell contact for optimal growth and survival. 3, 17 In the absence of stromal cells, BLIN-2 cultures undergo a reproducible pattern of slow apoptosis.
3,17 BLIN-2 cells cultured in optimum conditions (medium þ stromal cells) were treated individually or in combination with small molecular weight inhibitors of JAK, MEK, PI3K, Akt, or mTOR and analyzed for apoptosis, DNA synthesis and caspase activation. Our data indicate that stromal cell activation of the Raf/MEK/ERK, PI3K/Akt and JAK/STAT pathways synergize to promote B-ALL proliferation, but that B-ALL survival is mediated by crosstalk between PI3K, mTOR and the MEK pathways.
Methods

Cell culture
The establishment and characterization of the BLIN-2 cell line (pre-B-ALL) has been described previously by Shah et al. 3, 17 BLIN-2 cells were maintained in XVIVO-10 (BioWhittaker) medium at 1 Â 10 6 cells/ml in T-75 tissue culture flasks that had been previously seeded with a confluent monolayer of skin fibroblasts. 3 Experiments with inhibitors were carried out in 24-well plates that had also been seeded with a confluent monolayer of skin fibroblasts. BLIN-2 cells were plated at 1 Â 10 6 cells per well 24 h prior to adding the inhibitor. BLIN-2 cells do not adhere tightly to the stromal cell monolayer (which is adherent to plastic). Thus, BLIN-2 cells can be collected by gentle pipetting without disrupting the stromal cells. In all experiments, BLIN-2 cells were collected in this fashion so that there was no contribution of skin fibroblasts. For experiments without stromal cells, BLIN-2 cells were washed at least four times in medium and plated at a density of 1 Â 10 6 cells/ml.
Inhibitor treatment
The inhibitors and the concentrations used are as follows: AG490 (JAK2) 5 mM; LY294002 (PI3K) 3.3 mM; Rapamycin (mTOR) 1 mM; U0126 (MEK) 2 mM. In some experiments, the inhibitors were titrated to determine the lowest dose for use in subsequent experiments that resulted in specific kinase inhibition and induction of apoptosis. U0126 was purchased from Promega (Madison, WI, USA). Rapamycin was purchased from Sigma (St Louis, MO, USA). All others were obtained from Calbiochem (EMD Biosciences, La Jolla, CA, USA). Inhibitors were resuspended in DMSO as a vehicle. DMSO was used as a control for vehicle effects.
Measurement of caspase activity
Caspase activity was measured using the Apo Logixt Carboxyfluorescein Caspase (Cell Technology, Inc., Minneapolis, MN, USA) detection kit with slight modification of the manufacturer's protocol. Briefly, 1 Â 10 6 cells were collected and placed in a 12 Â 75 mm 2 polystyrene tube. The cells were pelleted by centrifugation and the media decanted. The cells were labeled by adding 10 ml of the FAM-peptide-fmk (caspase inhibitor) working dilution and incubating the cells at 371C for 1 h. Cells were washed twice with PBS þ 0.5% BSA and resuspended in 400 ml of PBS, followed by analysis using a FACScan flow cytometer (Becton Dickenson, San Jose, CA, USA).
AnnexinV/PI apoptosis assay
For each sample, approximately 1 Â 10 6 cells were washed twice with PBS and stained with 100 ml of labeling buffer (10 mM HEPES, 140 mM NaCl, 5 mM CaCl 2 , 0.5 mg propidium iodide, and 1 ml annexinV-fluos (Roche Applied Science, Indianapolis, IN, USA), and incubated at 41C for 20 min. The labeling buffer was aspirated and the cells were resuspended in 400 ml of binding buffer (10 mM HEPES, 140 mM NaCl, 5 mM CaCl 2 ). The cells were analyzed immediately using a FACScan flow cytometer (Becton Dickenson, San Jose, CA, USA).
[ 3 H]thymidine assay
Cells were seeded in a 96-well plate for 24 h. The following day, inhibitors were added. The cells were incubated for 24 h and [ 3 H]thymidine (6.7 Ci/mmol) (NEN, Boston, MA, USA) was added for the last 6 h. Cells were harvested and transferred onto filter mats and assayed with a scintillation counter.
Western blot analysis
Whole-cell lysates were prepared as described in Shelton et al 14 and separated on 8% SDS-PAGE gels, followed by transfer to nitrocellulose membranes. Membranes were blocked overnight at 41C in 1% BSA. Blots were probed sequentially with a phospho-specific antibody, the corresponding total antibody, and anti-b-tubulin as a loading control. Antibodies against phosphorylated and total p70S6K, ERK and Akt were purchased form Cell Signaling Technologies, Inc. (Beverly, MA, USA) and used as per the manufacturer's protocol.
Results
BLIN-2 is a pre-B-ALL (CD10
þ , CD19 þ , pre-B cell receptor þ ) cell line that requires viable bone marrow stromal cell or skin fibroblast cell contact for optimal growth and survival. 3, 17 In the absence of stromal cells, BLIN-2 cultures undergo a reproducible pattern of slow apoptosis over several days. 3, 17 These features make BLIN-2 an attractive model system for the study of interactions between B-lineage ALL and stromal cells. BLIN-2 cells were also treated with the mTOR inhibitor rapamycin. While rapamycin alone had little effect on BLIN-2 viability, treatment with mTOR þ MEK inhibitors together yielded similar results as PI3K þ MEK (Figure 1 ). This suggested that the promotion of cell viability by stromal cells through PI3K was mediated through mTOR in collaboration with activation of the MEK pathway. Interestingly, the combined treatment of mTOR þ PI3K inhibitors resulted in an increase in cell death (Figure 1a) . We have also observed synergy between these two inhibitors in terms of the induction of apoptosis in other cell systems. These results indicate that PI3K and mTOR pathways have some different downstream targets involved in the prevention of apoptosis in hematopoietic cells.
Combined inhibition of PI3K, MEK or JAK reduced BLIN-2 DNA synthesis. BLIN-2 cells were treated for 24 h with signaling pathway inhibitors in the presence of stromal cells and then (Figure 2) . However, cells treated with PI3K þ JAK, PI3K þ MEK or MEK þ JAK inhibitors exhibited a substantially higher inhibition of DNA synthesis, indicating that these combinations of inhibitors were sufficient to reduce DNA synthesis in BLIN-2 cells over a 24 h period beyond that observed upon stromal cell withdrawal. These experiments also indicated that some inhibitor combinations had greater effects (PI3K þ JAK, MEK þ JAK) on DNA synthesis than on the induction of apoptosis. As stromal cells are well documented for protecting quiescent cells from apoptosis, these findings likely have implications in targeting combinations of signaling pathways to rapidly sensitize ALL cells to apoptotic induction.
Caspase-3 and caspase-8 are activated upon treatment with inhibitors. Caspase activation upon treatment of BLIN-2 cells with the inhibitors was detected using a flow cytometric assay. In these experiments, cells were treated with permeable fluoresceinated FMK caspase inhibitors. These bind and inhibit activated caspases, permitting the analysis of a stable population. Caspase activity was observed as increased fluorescence.
As anticipated from the annexinV results, individual inhibitors exhibited little activation of caspase-3 ( Figure 3 ) or caspase-8 (Figure 4) , as compared with DMSO-treated cells. Treatment with PI3K þ MEK or mTOR þ MEK inhibitors resulted in more than 50% of the cells expressing activated caspase-3 and activated caspase-8 (Table 1) . A modest increase in cleaved caspase-3 and caspase-8 was observed with the other dual inhibitor combinations. Activation of caspase-8 with activated caspase-3 is a hallmark of death receptor-mediated apoptosis. Thus, these results are consistent with the hypothesis that inhibition of signaling pathways with small-molecule inhibitors may promote death receptor-mediated apoptosis, as has been shown for inhibition of heat shock proteins (reviewed in Creagh et al 21 ).
Confirmation of pathway inhibition
To verify pathway inhibition, BLIN-2 were treated with inhibitors of MEK, mTOR or PI3K for 24 h in the presence of stromal cells and then subjected to Western blot analysis to verify that downstream kinase activity of MEK, mTOR or PI3K was indeed inhibited. As shown in Figure 5 , treatment of BLIN-2 with inhibitors of mTOR, MEK or PI3K resulted in loss of phosphorylated p70S6K (Thr 389), ERK and Akt (Ser 473), respectively. Vehicle-treated cells (DSMO) did not exhibit evidence of signaling inhibition. These data confirm inhibition of the MEK, PI3K and mTOR pathways in BLIN-2 cells upon inhibitor treatment.
Discussion
Interactions between bone marrow stromal cells and lymphohematopoietic precursors are essential for regulation of hematopoietic cell growth, proliferation and differentiation. 1, [4] [5] [6] [7] [8] [9] [10] [11] 22, 23 The potential role for stromal cell interactions in the leukemogenic process, however, is only beginning to emerge. The expression of genes at the end of survival/growth cascades such as Bcl-2 has been shown to be increased upon culture of AML and ALL cells with stromal cell layers, accounting in part for protection of leukemic cells from chemotherapeutic agents. 6, 8 However, the specific molecular pathways activated in leukemic cells by stromal cell contact upstream of caspase and Bcl-2, which result in proliferation and/or apoptotic protection, are relatively unknown. Identification of such pathways may provide novel therapeutic targets. This is particularly relevant in light of studies demonstrating that stromal cell contact will protect ALL blasts from cytarabine-and etoposide-induced apoptosis.
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BLIN-2 is an established model system for studying interactions between B-cell precursor ALL and stromal cells.
3,17 BLIN-2 cells primarily exhibit a pre-B-cell phenotype and are pre-B-cell receptor positive. Upon stromal cell withdrawal, BLIN-2 cells undergo a reproducible pattern of slow programmed cell death over several days. 3, 17 In the experiments herein, foreskin fibroblasts were used to provide stromal cell support to BLIN- 2, as has been described previously. 3, 17 These cultures are capable of supporting the development of IgM þ immature Bcells from CD34 þ CD19 À precursors, as well as supporting the growth and differentiation of leukemic blasts. 24, 25 Thus, the stromal system we have used in these experiments recapitulates aspects of the normal bone marrow microenvironment that promote the differentiation, proliferation and survival of normal and leukemic human B-lineage cells.
In this study, we treated BLIN-2 cells cultured under optimal growth conditions of stromal cell contact with small molecular weight inhibitors of the MAPK, PI3K/Akt/mTOR or JAK/STAT signaling pathways. Based on these experiments, it appears that stromal cells participate in activating the Raf/MEK/ERK, PI3K/ mTOR and JAK/STAT pathways to promote BLIN-2 growth and survival. At least two of these pathways must be inhibited before BLIN-2 proliferation is arrested, suggesting the existence of crosstalk between the pathways. Minimal effects were observed when BLIN-2 cells were treated with individual inhibitors.
In summary, we provide evidence that stromal cell-derived mechanism(s) promoting B-lineage ALL apoptotic resistance can be uncoupled from those that promote proliferation through the use of small-molecule inhibitors. One role of the stromal cell microenvironment in normal hematopoiesis is to protect quiescent populations of precursor cells from apoptosis (Bertrand et al 1 and references therein). Thus, the identification and inhibition of signaling pathways in hematological malignancies that lead to loss of apoptotic protection vs arrested proliferation in the context of stromal cell support is crucial for the development of novel therapeutic targets. These studies document the utility of using a stromal cell-dependent B-ALL model system and small-molecule inhibitors to identify pathways activated by the stromal cell microenvironment that modulate ALL proliferation and apoptotic protection.
